Kymera Therapeutics Inc (KYMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has a cash flow conversion efficiency ratio of -0.036x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.06 Million) by net assets ($1.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kymera Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Kymera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Kymera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kymera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kymera Therapeutics Inc ranked by their cash flow conversion efficiency. See Kymera Therapeutics Inc (KYMR) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OGE Energy Corporation
NYSE:OGE
|
-0.003x |
|
Godaddy Inc
NYSE:GDDY
|
1.987x |
|
FirstCash Inc
NASDAQ:FCFS
|
0.076x |
|
MOWI ASA SP.ADR
F:PNDA
|
0.030x |
|
Founder Technology Group Co Ltd
SHG:600601
|
0.084x |
|
Ingenic Semiconductor
SHE:300223
|
0.006x |
|
Skechers USA Inc
NYSE:SKX
|
0.103x |
|
Freedom Holding Corp
NASDAQ:FRHC
|
-0.993x |
Annual Cash Flow Conversion Efficiency for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Kymera Therapeutics Inc from 2018 to 2025. View latest Kymera Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.58 Billion | $-232.89 Million | -0.147x | +36.66% |
| 2024-12-31 | $835.62 Million | $-194.50 Million | -0.233x | +10.59% |
| 2023-12-31 | $394.97 Million | $-102.83 Million | -0.260x | +16.64% |
| 2022-12-31 | $490.15 Million | $-153.09 Million | -0.312x | -11.33% |
| 2021-12-31 | $459.64 Million | $-128.95 Million | -0.281x | -190.37% |
| 2020-12-31 | $283.89 Million | $88.13 Million | 0.310x | +229.01% |
| 2019-12-31 | $-74.41 Million | $17.91 Million | -0.241x | -146.39% |
| 2018-12-31 | $-34.44 Million | $-17.86 Million | 0.519x | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more